Search

Your search keyword '"Montano, Massimo"' showing total 14 results
Start Over Author "Montano, Massimo"
14 results on '"Montano, Massimo"'

1. Translational Insights in the Landscape of Salivary Gland Cancers: Ready for a New Era?

Author

Perri, Francesco, primary, Fusco, Roberta, additional, Sabbatino, Francesco, additional, Fasano, Morena, additional, Ottaiano, Alessandro, additional, Cascella, Marco, additional, Marciano, Maria Luisa, additional, Pontone, Monica, additional, Salzano, Giovanni, additional, Maiello, Maria Elena, additional, Montano, Massimo, additional, Calogero, Ester, additional, D’Aniello, Roberta, additional, Maiolino, Piera, additional, Ciardiello, Fortunato, additional, Zotta, Alessia, additional, Alfieri, Salvatore, additional, and Ionna, Franco, additional

Published
2024
Full Text
View/download PDF

4. Impact of Epstein Barr Virus Infection on Treatment Opportunities in Patients with Nasopharyngeal Cancer

Author

Perri, Francesco, primary, Sabbatino, Francesco, additional, Ottaiano, Alessandro, additional, Fusco, Roberta, additional, Caraglia, Michele, additional, Cascella, Marco, additional, Longo, Francesco, additional, Rega, Rosalia Anna, additional, Salzano, Giovanni, additional, Pontone, Monica, additional, Marciano, Maria Luisa, additional, Piccirillo, Arianna, additional, Montano, Massimo, additional, Fasano, Morena, additional, Ciardiello, Fortunato, additional, Della Vittoria Scarpati, Giuseppina, additional, and Ionna, Franco, additional

Published
2023
Full Text
View/download PDF

5. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study)

Author

Leone, Francesco, Marino, Donatella, Cereda, Stefano, Filippi, Roberto, Belli, Carmen, Spadi, Rosella, Nasti, Guglielmo, Montano, Massimo, Amatu, Alessio, Aprile, Giuseppe, Cagnazzo, Celeste, Fasola, Gianpiero, Siena, Salvatore, Ciuffreda, Libero, Reni, Michele, and Aglietta, Massimo

Published
2016
Full Text
View/download PDF

7. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study)

Author

Leone, Francesco, Marino, Donatella, Cereda, Stefano, Filippi, Roberto, Belli, Carmen, Spadi, Rosella, Nasti, Guglielmo, Montano, Massimo, Amatu, Alessio, Aprile, Giuseppe, Cagnazzo, Celeste, Fasola, Gianpiero, Siena, Salvatore, Ciuffreda, Libero, Reni, Michele, and Aglietta, Massimo

Subjects
Adult, Male, Cancer Research, Organoplatinum Compounds, Adenocarcinoma, chemotherapy, Deoxycytidine, Disease-Free Survival, Cholangiocarcinoma, Proto-Oncogene Proteins p21(ras), Bile Ducts, Extrahepatic, Antineoplastic Combined Chemotherapy Protocols, KRAS, Humans, Aged, Panitumumab, Antibodies, Monoclonal, Middle Aged, Prognosis, Gemcitabine, gemcitabine and oxaliplatin (GEMOX), ErbB Receptors, Oxaliplatin, Bile Ducts, Intrahepatic, Biliary Tract Neoplasms, Treatment Outcome, Oncology, Bile Duct Neoplasms, biliary cancer, Female, Gallbladder Neoplasms, cholangiocarcinoma, panitumumab
Abstract

Biliary tract cancer (BTC) is a rare and lethal disease with few therapeutic options. Preclinical data suggest that the epidermal growth factor receptor (EGFR) pathway could be involved in its progression.This open-label, randomized phase 2 trial recruited chemotherapy-naive patients with advanced BTC displaying a wild-type (WT) KRAS status. Patients were randomized to gemcitabine (1000 mg/m(2) ) and oxaliplatin (100 mg/m(2) ) with (arm A) or without (arm B) panitumumab (6 mg/kg) for up to 12 cycles. The primary endpoint was progression-free survival (PFS) analyzed in an intention-to-treat fashion.Eighty-nine patients (45 in arm A and 44 in arm B) were enrolled between June 2010 and September 2013. After a median follow-up of 10.1 months, the median PFS was 5.3 months (95% confidence interval, 3.3-7.2 months) in arm A and 4.4 months (95% confidence interval, 2.6-6.2 months) in arm B (P = .27). No survival differences were observed: the median overall survival was 9.9 months in arm A and 10.2 months in arm B (P = .42). In a subgroup analysis, no differences in PFS according to the site of the primary tumor were observed; patients with intrahepatic cholangiocarcinoma treated with panitumumab may have had a survival benefit in comparison with the control group (15.1 vs 11.8 months, P = .13). As for safety, skin toxicity was the main adverse event in arm A (80% of the patients). A higher incidence of diarrhea (55.5% vs 31.8%), mucositis (22.2% vs 13.6%), and constipation (24.4% vs 15.9%) was seen in arm A.These results confirm the marginal role of anti-EGFR therapy even for WT KRAS-selected BTC.

Published
2015

8. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial

Author

Caponigro, Francesco, primary, Di Gennaro, Elena, additional, Ionna, Franco, additional, Longo, Francesco, additional, Aversa, Corrado, additional, Pavone, Ettore, additional, Maglione, Maria Grazia, additional, Di Marzo, Massimiliano, additional, Muto, Paolo, additional, Cavalcanti, Ernesta, additional, Petrillo, Antonella, additional, Sandomenico, Fabio, additional, Maiolino, Piera, additional, D’Aniello, Roberta, additional, Botti, Gerardo, additional, De Cecio, Rossella, additional, Losito, Nunzia Simona, additional, Scala, Stefania, additional, Trotta, Annamaria, additional, Zotti, Andrea Ilaria, additional, Bruzzese, Francesca, additional, Daponte, Antonio, additional, Calogero, Ester, additional, Montano, Massimo, additional, Pontone, Monica, additional, De Feo, Gianfranco, additional, Perri, Francesco, additional, and Budillon, Alfredo, additional

Published
2016
Full Text
View/download PDF

9. Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial)

Author

Avallone, Antonio, Piccirillo, Maria Carmela, Delrio, Paolo, Pecori, Biagio, Di Gennaro, Elena, Aloj, Luigi, Tatangelo, Fabiana, D'Angelo, Valentina, Granata, Cinzia, Cavalcanti, Ernesta, Maurea, Nicola, Maiolino, Piera, Bianco, Franco, Montano, Massimo, Silvestro, Lucrezia, Terranova Barberio, Manuela, Roca, Maria Serena, Di Maio, Massimo, Marone, Pietro, Botti, Gerardo, Petrillo, Antonella, Daniele, Gennaro, Lastoria, Secondo, Iaffaioli, Vincenzo R, Romano, Giovanni, Caracò, Corradina, Muto, Paolo, Gallo, Ciro, Perrone, Francesco, Budillon, Alfredo, Aloj, Luigi [0000-0002-7452-4961], and Apollo - University of Cambridge Repository

Subjects
Adult, Male, Adolescent, Radiotherapy, Rectal Neoplasms, Valproic Acid, Middle Aged, Combined Modality Therapy, Deoxycytidine, Young Adult, Research Design, Antineoplastic Combined Chemotherapy Protocols, Preoperative Care, Humans, Female, Fluorouracil, Capecitabine, Aged
Abstract

BACKGROUND: Locally advanced rectal cancer (LARC) is a heterogeneous group of tumors where a risk-adapted therapeutic strategy is needed. Short-course radiotherapy (SCRT) is a more convenient option for LARC patients than preoperative long-course RT plus capecitabine. Histone-deacetylase inhibitors (HDACi) have shown activity in combination with RT and chemotherapy in the treatment of solid tumors. Valproic acid (VPA) is an anti-epileptic drug with HDACi and anticancer activity. In preclinical studies, our group showed that the addition of HDACi, including VPA, to capecitabine produces synergistic antitumour effects by up-regulating thymidine phosphorylase (TP), the key enzyme converting capecitabine to 5-FU, and by downregulating thymidylate synthase (TS), the 5-FU target. METHODS/DESIGN: Two parallel phase-1 studies will assess the safety of preoperative SCRT (5 fractions each of 5 Gy, on days 1 to 5) combined with (a) capecitabine alone (increasing dose levels: 500-825 mg/m2/bid), on days 1-21, or (b) capecitabine as above plus VPA (oral daily day -14 to 21, with an intra-patient titration for a target serum level of 50-100 microg/ml) followed by surgery 8 weeks after the end of SCRT, in low-moderate risk RC patients. Also, a randomized phase-2 study will be performed to explore whether the addition of VPA and/or capecitabine to preoperative SCRT might increase pathologic complete tumor regression (TRG1) rate. A sample size of 86 patients (21-22/arm) was calculated under the hypothesis that the addition of capecitabine or VPA to SCRT can improve the TRG1 rate from 5% to 20%, with one-sided alpha = 0.10 and 80% power.Several biomarkers will be evaluated comparing normal mucosa with tumor (TP, TS, VEGF, RAD51, XRCC1, Histones/proteins acetylation, HDAC isoforms) and on blood samples (polymorphisms of DPD, TS, XRCC1, GSTP1, RAD51 and XRCC3, circulating endothelial and progenitors cells; PBMCs-Histones/proteins acetylation). Tumor metabolism will be measured by 18FDG-PET at baseline and 15 days after the beginning of SCRT. DISCUSSION: This project aims to improve the efficacy of preoperative treatment of LARC and to decrease the inconvenience and the cost of standard long-course RT. Correlative studies could identify both prognostic and predictive biomarkers and could add new insight in the mechanism of interaction between VPA, capecitabine and RT.EudraCT Number: 2012-002831-28. TRIAL REGISTRATION: ClinicalTrials.gov number, NCT01898104.

Published
2014

10. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-typeKRASadvanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study)

Author

Leone, Francesco, primary, Marino, Donatella, additional, Cereda, Stefano, additional, Filippi, Roberto, additional, Belli, Carmen, additional, Spadi, Rosella, additional, Nasti, Guglielmo, additional, Montano, Massimo, additional, Amatu, Alessio, additional, Aprile, Giuseppe, additional, Cagnazzo, Celeste, additional, Fasola, Gianpiero, additional, Siena, Salvatore, additional, Ciuffreda, Libero, additional, Reni, Michele, additional, and Aglietta, Massimo, additional

Published
2015
Full Text
View/download PDF

11. A phase II, open-label, randomized clinical trial of panitumumab plus gemcitabine and oxaliplatin (GEMOX) versus GEMOX alone as first-line treatment in advanced biliary tract cancer: The Vecti-BIL study.

Author

Leone, Francesco, primary, Marino, Donatella, additional, Filippi, Roberto, additional, Cereda, Stefano, additional, Belli, Carmen, additional, Spadi, Rosella, additional, Nasti, Guglielmo, additional, Montano, Massimo, additional, Amatu, Alessio, additional, Aprile, Giuseppe, additional, Cagnazzo, Celeste, additional, Fasola, Gianpiero, additional, Siena, Salvatore, additional, Ciuffreda, Libero, additional, Reni, Michele, additional, and Aglietta, Massimo, additional

Published
2015
Full Text
View/download PDF

12. Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid - short RadioTherapy - rectum 3rd trial)

Author

Avallone, Antonio, primary, Piccirillo, Maria Carmela, additional, Delrio, Paolo, additional, Pecori, Biagio, additional, Di Gennaro, Elena, additional, Aloj, Luigi, additional, Tatangelo, Fabiana, additional, D’Angelo, Valentina, additional, Granata, Cinzia, additional, Cavalcanti, Ernesta, additional, Maurea, Nicola, additional, Maiolino, Piera, additional, Bianco, Franco, additional, Montano, Massimo, additional, Silvestro, Lucrezia, additional, Terranova Barberio, Manuela, additional, Roca, Maria Serena, additional, Di Maio, Massimo, additional, Marone, Pietro, additional, Botti, Gerardo, additional, Petrillo, Antonella, additional, Daniele, Gennaro, additional, Lastoria, Secondo, additional, Iaffaioli, Vincenzo R, additional, Romano, Giovanni, additional, Caracò, Corradina, additional, Muto, Paolo, additional, Gallo, Ciro, additional, Perrone, Francesco, additional, and Budillon, Alfredo, additional

Published
2014
Full Text
View/download PDF

14. Prognostic and predictive response factors in colorectal cancer patients: between hope and reality.

Author

De Divitiis C, Nasti G, Montano M, Fisichella R, Iaffaioli RV, and Berretta M

Subjects
Antineoplastic Agents adverse effects, Biomarkers, Tumor genetics, Biomarkers, Tumor metabolism, Colorectal Neoplasms genetics, Colorectal Neoplasms metabolism, Colorectal Neoplasms mortality, Colorectal Neoplasms pathology, Early Detection of Cancer, Humans, Molecular Targeted Therapy, Multimodal Imaging, Neoplasm Staging, Patient Selection, Positron-Emission Tomography, Precision Medicine, Predictive Value of Tests, Risk Factors, Time Factors, Tomography, X-Ray Computed, Treatment Outcome, Antineoplastic Agents therapeutic use, Colorectal Neoplasms drug therapy
Abstract

Colorectal cancer (CRC) represents one of the most commonly diagnosed cancers worldwide. It is the second leading cause of cancer death in Western Countries. In the last decade the survival of patients with metastatic CRC has improved dramatically. Due to the advent of new drugs (irinotecan and oxaliplatin) and target therapies (i.e., bevacizumab, cetuximab and panitumab), the median overall survival has risen from about 12 mo in the mid nineties to 30 mo recently. Many questions needing of right collocations and more clearness still exist regarding the prognostic factors and the predictive factors of response to therapy. Despite advances in dosing and scheduling of chemotherapy in both adjuvant and advanced settings, and a greater emphasis on early detection, the outlook still remains poor for most patients. Molecular analyses have shown that the natural history of all CRCs is not the same. Individual patients with same stage tumours may have different long term prognosis and response to therapy. In addition, some prognostic variables are likely to be more important than others. Here we review the role of prognostic factors and predictive factors according to the recently published English literature.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results